Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

Cassava Sciences Inc. stock grades by Barron's. View SAVA fundamental and sentiment analysis powered by MarketGrader.

NEW YORK, March 26 (Reuters) - The biotechnology company Cassava Sciences (SAVA.O) failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation of all ongoing trials. Read more here.

In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer’s ...

Present Market Standing of Cassava Sciences Trading volume stands at 3,473,313, with SAVA's price down by -13.12%, positioned at $27.69.

Shares of Cassava Sciences(NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came ...